Champions Oncology, Inc. CSBR
We take great care to ensure that the data presented and summarized in this overview for CHAMPIONS ONCOLOGY, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CSBR
View all-
Battery Management Corp. Boston, MA2.42MShares$10.4 Million3.63% of portfolio
-
Nea Management Company, LLC Timonium, MD1.71MShares$7.39 Million0.64% of portfolio
-
Tocqueville Asset Management L.P. New York, NY705KShares$3.04 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA307KShares$1.32 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny120KShares$517,1610.0% of portfolio
-
Black Rock Inc. New York, NY116KShares$500,2700.0% of portfolio
-
Geode Capital Management, LLC Boston, MA65.1KShares$280,4250.0% of portfolio
-
Act Capital Management, LLC Wayne, PA62.5KShares$269,3750.65% of portfolio
-
Morgan Stanley New York, NY57.8KShares$249,1170.0% of portfolio
-
Goldman Sachs Group Inc New York, NY48.4KShares$208,6600.0% of portfolio
Latest Institutional Activity in CSBR
Top Purchases
Top Sells
About CSBR
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Insider Transactions at CSBR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 31
2024
|
Joel Ackerman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
105,137
+5.13%
|
$315,411
$3.77 P/Share
|
|
Jan 12
2024
|
Daniel Newman Mendelson Director |
BUY
Open market or private purchase
|
Direct |
1,000
+0.5%
|
$6,000
$6.5 P/Share
|
|
Jan 11
2024
|
Daniel Newman Mendelson Director |
BUY
Open market or private purchase
|
Direct |
2,000
+1.0%
|
$12,000
$6.27 P/Share
|
|
Jan 10
2024
|
Daniel Newman Mendelson Director |
BUY
Open market or private purchase
|
Direct |
2,944
+1.48%
|
$17,664
$6.31 P/Share
|
|
Jan 09
2024
|
Daniel Newman Mendelson Director |
BUY
Open market or private purchase
|
Direct |
3,000
+1.53%
|
$18,000
$6.25 P/Share
|
|
Jan 08
2024
|
Daniel Newman Mendelson Director |
BUY
Open market or private purchase
|
Direct |
1,000
+0.52%
|
$6,000
$6.15 P/Share
|
|
Jan 05
2024
|
Daniel Newman Mendelson Director |
BUY
Open market or private purchase
|
Direct |
2,000
+1.05%
|
$12,000
$6.09 P/Share
|
|
Jan 04
2024
|
Daniel Newman Mendelson Director |
BUY
Open market or private purchase
|
Direct |
3,000
+1.58%
|
$18,000
$6.12 P/Share
|
|
Jan 03
2024
|
Daniel Newman Mendelson Director |
BUY
Open market or private purchase
|
Direct |
500
+0.27%
|
$2,500
$5.83 P/Share
|
|
Dec 21
2023
|
Daniel Newman Mendelson Director |
BUY
Open market or private purchase
|
Direct |
2,500
+1.35%
|
$10,000
$4.92 P/Share
|
|
Dec 20
2023
|
Daniel Newman Mendelson Director |
BUY
Open market or private purchase
|
Direct |
2,100
+1.15%
|
$8,400
$4.82 P/Share
|
|
Dec 19
2023
|
Daniel Newman Mendelson Director |
BUY
Open market or private purchase
|
Direct |
5,000
+2.72%
|
$20,000
$4.75 P/Share
|
|
Oct 17
2023
|
Joel Ackerman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
114,552
+11.79%
|
$229,104
$2.1 P/Share
|
|
Oct 11
2023
|
Daniel Newman Mendelson Director |
BUY
Open market or private purchase
|
Direct |
5,000
+2.97%
|
$30,000
$6.4 P/Share
|
|
Oct 10
2023
|
Daniel Newman Mendelson Director |
BUY
Open market or private purchase
|
Direct |
1,100
+0.69%
|
$6,600
$6.41 P/Share
|
|
Oct 06
2023
|
Daniel Newman Mendelson Director |
BUY
Open market or private purchase
|
Direct |
1,530
+0.97%
|
$9,180
$6.48 P/Share
|
|
Oct 05
2023
|
Daniel Newman Mendelson Director |
BUY
Open market or private purchase
|
Direct |
2,000
+1.27%
|
$12,000
$6.47 P/Share
|
|
Oct 04
2023
|
Daniel Newman Mendelson Director |
BUY
Open market or private purchase
|
Direct |
5,000
+3.16%
|
$30,000
$6.4 P/Share
|
|
Oct 03
2023
|
Daniel Newman Mendelson Director |
BUY
Open market or private purchase
|
Direct |
2,500
+1.66%
|
$15,000
$6.3 P/Share
|
|
Sep 29
2023
|
Daniel Newman Mendelson Director |
BUY
Open market or private purchase
|
Direct |
4,000
+2.25%
|
$24,000
$6.16 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 105K shares |
|---|---|
| Open market or private purchase | 25K shares |